OncoCyte (OCX) Stock Price, News & Analysis

Company Overview

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Key Stats

• Today's Range: $2.01 to $2.06
• 50-Day Range: $1.96 to $2.71
• 52-Week Range: $1.92 to $3.48
• Volume: 6,162 shs
• Average Volume: 33,840 shs
• Market Capitalization: $33.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.42
• Consensus Rating: Moderate Buy

OncoCyte Stock Analysis - MarketRank™

OncoCyte scored higher than 70% of companies evaluated by MarketBeat, and ranked 516th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

OncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

OncoCyte has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OncoCyte are expected to grow in the coming year, from ($2.57) to ($1.40) per share.

Price to Book Value per Share Ratio

OncoCyte has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.42% of the float of OncoCyte has been sold short.

Short Interest Ratio / Days to Cover

OncoCyte has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in OncoCyte has recently decreased by 0.09%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OncoCyte does not currently pay a dividend.

Dividend Growth

OncoCyte does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.42% of the float of OncoCyte has been sold short.

Short Interest Ratio / Days to Cover

OncoCyte has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in OncoCyte has recently decreased by 0.09%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

OncoCyte has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for OncoCyte this week, compared to 1 article on an average week.

Search Interest

2 people have searched for OCX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, OncoCyte insiders have bought more of their company's stock than they have sold. Specifically, they have bought $276,133.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 1.58% of the stock of OncoCyte is held by insiders.

Percentage Held by Institutions

55.35% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OCX Stock Analysis - Frequently Asked Questions

How have OCX shares performed this year?

OncoCyte's stock was trading at $2.38 at the start of the year. Since then, OCX shares have decreased by 14.1% and is now trading at $2.0440.
View the best growth stocks for 2025 here.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NASDAQ:OCX) announced its earnings results on Tuesday, November, 12th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.54. The firm had revenue of $0.12 million for the quarter. OncoCyte had a negative net margin of 6,122.29% and a negative trailing twelve-month return on equity of 269.32%.

When did OncoCyte's stock split?

Shares of OncoCyte reverse split on the morning of Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are OncoCyte's major shareholders?

Top institutional shareholders of OncoCyte include FNY Investment Advisers LLC (0.29%). Insiders that own company stock include Broadwood Partners, LP, Pura Vida Investments, Llc, Andrew Arno, Andrea S James, Alfred D Kingsley, Ronald Asbury Andrews, Andrew J Last, Josh Riggs, Li Yu, Douglas T Ross, Gisela Paulsen and Cavan M Redmond.
View institutional ownership trends.

How do I buy shares of OncoCyte?

Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of OncoCyte own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OncoCyte investors own include Alibaba Group (BABA), Meta Platforms (META), Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY) and Ford Motor (F).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 1/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OCX
• CUSIP: N/A
• CIK: 1642380
• Web: oncocyte.com
• Phone: (949) 409-7600
• Fax: 510-521-3389
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.42
• High Stock Price Target: $5.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +116.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-27,780,000.00
• Net Margins: -6,122.29%
• Pretax Margin: -6,085.19%
• Return on Equity: -269.32%
• Return on Assets: -59.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.53
• Quick Ratio: 0.50

Sales & Book Value

• Annual Sales: $1.50 million
• Price / Sales: 22.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.48 per share
• Price / Book: 0.82

Miscellaneous

• Outstanding Shares: 16,830,000
• Free Float: 16,569,000
• Market Cap: $34.40 million
• Optionable: No Data
• Beta: 0.90